In this study, we demonstrated that chelidonine treatment reduced FOXM1 and PLK1 expression, which implied that chelidonine may inhibit proliferation of BC cells by inhibiting the AKT/FOXO3/FOXM1 pathway. Here, PLK1 is linked to breast cancer.